What is Amplified Sciences?
Amplified Sciences is a clinical-stage diagnostics company focused on pioneering diagnostic tests for the early detection, risk stratification, and monitoring of complex diseases. The company leverages a proprietary ultra-sensitive optical reporter platform technology to create a new generation of multi-omics diagnostic tests. Its lead product, PanCystPro, is engineered to identify biomarker levels within pancreatic cyst fluid, aiding in the assessment of patients at elevated risk for pancreatic cancer. Amplified Sciences is committed to equipping clinicians with precise tools to enhance diagnostic accuracy and improve patient treatment outcomes.
How much funding has Amplified Sciences raised?
Amplified Sciences has raised a total of $2.4M across 3 funding rounds:
Debt
$15K
Angel/Seed
$1.8M
Debt
$550K
Debt (2021): $15K with participation from PPP
Angel/Seed (2021): $1.8M led by Purdue Ventures, OCA Ventures, and Elevate Ventures
Debt (2025): $550K, investors not publicly disclosed
Key Investors in Amplified Sciences
Purdue Ventures
Purdue Ventures is an investor focused on supporting innovative ventures, likely with an interest in technology and scientific advancements. Their participation suggests a belief in Amplified Sciences' technological platform and market potential.
OCA Ventures
OCA Ventures is dedicated to assisting entrepreneurs in the development of successful companies. They provide support and resources to help startups thrive in their respective markets. Their focus is on fostering innovation and growth among emerging businesses.
Elevate Ventures
Elevate Ventures is an active participant in shaping the future of Indiana by investing in cross-sector innovation-driven companies at Pre-Seed, Seed, and Series A stages. They provide funding and guidance for entrepreneurs and seek founders with grit, creativity, and coachability.
What's next for Amplified Sciences?
With the recent influx of major strategic investment, Amplified Sciences is poised to accelerate the development and commercialization of its advanced diagnostic solutions. The company's focus on multi-omics and its proprietary platform technology position it for significant growth in the competitive diagnostics market. Future endeavors will likely involve expanding the application of its technology to a broader range of diseases and further validating PanCystPro's clinical utility, aiming to solidify its market presence and drive improved patient care.
See full Amplified Sciences company page
